
SGMT Stock Forecast & Price Target
SGMT Analyst Ratings
Bulls say
Sagimet Biosciences is a promising company with strong financial backing and potential in the dermatology market. With a focus on developing therapies for MASH and acne, they have shown positive results in their ongoing Phase 3 trial for denifanstat and are confident in the potential success of their drug TVB-3567 in their Phase 1 trial. Their innovative approach to targeting dysfunctional metabolic and fibrotic pathways in diseases sets them apart in the biopharmaceutical industry.
Bears say
Sagimet Biosciences is facing many challenges as they pivot from developing a drug for fatty liver disease to an acne treatment, resulting in a negative outlook for their stock. Analysts have updated their models to reflect a shift in focus from MASH to acne, leading to a decrease in peak sales projections. Additionally, the company's cash flow is now heavily relied upon by investors to fund the development of their pipeline, creating an uncertain financial future.
This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SGMT Analyst Forecast & Price Prediction
Start investing in SGMT
Order type
Buy in
Order amount
Est. shares
0 shares